Edit

Fore Bio

http://www.fore.bio/
Last activity: 14.07.2026
Probably Closed
Categories: BioTechHealthcareLifeSciencesOncologyTherapeutics
A personalized medicine diagnostics company assessing the activity of mutations and combination of mutations and their response to targeted drugs
Mentions
15
Location: United States
Total raised: $180.4M

Investors 3

Funding Rounds 3

DateSeriesAmountInvestors
14.07.2026-$67.4MHBM Health...
23.05.2025Series D$38M-
25.08.2023Series D$75M-

Mentions in press and media 15

DateTitleDescription
14.07.2026FORE Biotherapeutics Inks $67.4 Million Series D-2 Extension PHILADELPHIA, PA, FORE Biotherapeutics, a company dedicated to developing targeted therapies to treat patients with cancer, announced the closing of an upsized Series D-2 extension financing of $67.4 million. >> Click here for more f...
11.07.2026FORE Biotherapeutics Secures $110M Total Funding for Groundbreaking BRAF Cancer DrugFORE Biotherapeutics secured $67.4 million, completing its Series D-2 funding at $110 million. This capital fuels plixorafenib, a next-generation BRAF inhibitor. The drug targets challenging BRAF-altered cancers, including primary CNS tumor...
10.07.2026FORE Biotherapeutics Raises $67.4 Million In Series D-2 Extension To Advance PlixorafenibFORE Biotherapeutics, a registration-stage oncology company focused on targeted cancer therapies, announced the closing of an upsized $67.4 million Series D-2 extension financing, bringing the total raised in the Series D-2 round to $110 mi...
08.07.2026Arkenstone Defense Raises $35M to Simplify Government ContractingArkenstone Defense Raises $35M Seed Round Arkenstone Defense has emerged from stealth after raising $35 million in seed funding to simplify government contracting for commercial technology companies. The round was led by J2 Ventures, with p...
08.07.2026FORE Biotherapeutics Raises $67.4M to Advance BRAF Cancer TherapyFORE Biotherapeutics Expands Funding for Late-Stage Cancer Program FORE Biotherapeutics has raised $67.4 million to support the development of its lead targeted cancer therapy, plixorafenib. The round was co-led by SR One, Medicxi, SymBiosi...
08.07.2026FORE Biotherapeutics Raises $67.4M in Series D-2 Extension FundingFore Biotherapeutics, a Philadelphia, PA-based registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, raised $67.4M in Series D-2 extension funding. The round was led by SR One, ...
28.05.2025FORE Biotherapeutics: A New Dawn in Cancer Treatment with $38 Million Series D-2 FinancingIn the ever-evolving landscape of cancer treatment, a new player is making waves. FORE Biotherapeutics, based in Philadelphia, has secured $38 million in Series D-2 financing. This funding marks a significant step forward in the company's m...
23.05.2025FORE Biotherapeutics Raises $38 Million in Series D-2 Financing for the Continued Advancement of Plixorafenib-
23.05.2025Fore Biotherapeutics Raises $38M in Series D-2 FinancingFore Biotherapeutics, a Philadelphia, PA-based registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, raised $38M ion Series D-2 financing. Backers included R One, Medicxi, OrbiM...
23.05.2025FORE Biotherapeutics: $38 Million Series D-2 Raised For Advancement Of PlixorafenibFORE Biotherapeutics, a registration-stage biotherapeutics company focused on developing targeted therapies to treat cancer patients, announced a $38 million Series D-2 financing. For this initial close of the Series D-2, leading healthcare...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In